- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
Status
Completed
Phase
III
Principal Investigator(s)
Jean-Michel Molina, MD
Objective
Designed to evaluate a strategy for the prevention of HIV infection including "on demand" antiretroviral pre-exposure with Truvada versus placebo, associated with overall prevention (counseling, condoms, STD screening, HBV and HAV vaccinations and post-exposure treatment of HIV infection) in MSM, exposed to the risk of HIV infection.
Randomization stopped in October 2014 after DSMB examination of data showed PrEP was protective against HIV. All trial participants offered PrEP “on demand.” Trial to continue for one year to demonstrate long-term benefit and safety of “on demand” PrEP. As of April 2016, follow-up is continuing.
Prevention Option(s)
PrEP
Study Design
Controlled
Randomized
Double-blind
Arms and Assigned Interventions
Description
2 tablets of truvada within 24 hours before first sexual relations, then 1 tablet of Truvada during the period of sexual activity including the last sexual intercourse, finally, a last dose of 1 tablet of Truvada approximately 24 hours later
Other Name: tenofovir disoproxil and emtricitabine
Mode of Delivery
Tablet
Products
TDF/FTC (Truvada)
ARMs
Experimental
Description
2 tablets of placebo within 24 hours before first sexual relations, then 1 tablet of placebo every 24 hours during the period of sexual activity including the last sexual intercourse, finally, a last dose of 1 tablet of placebo approximatively 24 hours later
Mode of Delivery
Tablet
ARMs
Placebo Comparator
Official Code
Trial Sponsors
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS), the Canadian Trial network, Bill and Melinda Gates Foundation, Fondation Pierre Bergé, Gilead Sciences
February 2012
June 2016
Enrollment
1 900
18
Years
Population
MSM
Sites
CHUM - Hôpital Hôtel Dieu
Montréal, Canada
Canada
Hôpital de La Croix Rousse
Lyon
France
CHU Hôtel Dieu
Nantes
France
Hôpital de l'Archet
Nice
France
Hôpital Tenon
Paris
France
Hôpital Saint-Louis
Paris
France
Hôpital Gustave Dron
Tourcoing
France